Idorsia (OTCMKTS:IDRSF) Trading Down 1.9% – Here’s Why

Posted by Geri Gentry on Aug 14th, 2026

Idorsia Ltd (OTCMKTS:IDRSF – Get Free Report) traded down 1.9% during mid-day trading on Thursday . The stock traded as low as $7.75 and last traded at $7.75. Approximately 2,850 shares were traded during trading, a decline of 74% from the average daily volume of 11,030 shares. The stock had previously closed at $7.90.

Analyst Ratings Changes

Separately, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Idorsia in a research note on Monday, August 3rd. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat, Idorsia has a consensus rating of “Moderate Buy”.

View Our Latest Stock Analysis on IDRSF

Idorsia Price Performance

The stock’s fifty day moving average is $7.28 and its 200-day moving average is $5.61.

About Idorsia

(Get Free Report)

Idorsia Ltd is a Swiss biopharmaceutical company founded in 2017 as a spin-off from Actelion following its acquisition by Johnson & Johnson. Headquartered in Allschwil, Switzerland, Idorsia focuses on the discovery, development and commercialization of innovative small-molecule therapeutics. The company’s R&D efforts span multiple therapeutic areas, including neuroscience, cardiovascular and immunology, with the goal of addressing unmet medical needs through novel mechanisms of action.

Among Idorsia’s lead products is daridorexant, a dual orexin receptor antagonist developed for the treatment of insomnia.